HAIFA, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today issued the following shareholder update from Chief Executive Officer and President, Yaky Yanay: As we move forward, we are actively positioning the Company for sustained growth, increased revenue streams, and the expansion of our operations. We are currently ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from __________ to __________ Commission file number 001-31392 | Nevada | 98-0351734 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identi ...

HAIFA, Israel, April 28, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced the completion of the acquisition of approximately 71% of the equity of Kokomodo Ltd. ("Kokomodo"), an innovative AgFoodTech company specializing in cultivated cacao production, for $4.5 million payable in 976,139 of the Company's Common S ...

NEW YORK, April 21, 2025 /PRNewswire/ -- DarioHealth Corp. (NASDAQ: DRIO) ("Dario" or the "Company"), a leading global digital health company, today announced that Zvi Ben-David, Chief Financial Officer, will retire from his role, effective May 15, 2025. The Company has appointed Chen Franco-Yehuda as its new Chief Financial Officer, Treasurer, and Secretary, and will assume the role upon Mr. Ben-David's retirement on May 15, 2025. To ensure a smooth transition, Mr. Ben-David will remain with the Company un ...

Latest granted patents reinforce Pluri's position as a leader in Mucosal-Associated Invariant T ("MAIT") cell-based cell therapies for solid cancersPluri's MAIT platform enables commercial scale production of powerful immune cells as a potential first-in-class, ready to use, "off-the-shelf" therapy for cancer patientsPluri's MAIT platform addresses the global immune cell engineering market, projected to reach approximately $11.7 billion by 2030, and the global cancer immunotherapy market, calculated at $136 ...

Core Viewpoint - Pluri Inc. has entered into an exclusive collaboration with Hemafund Ltd. to develop and distribute PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS) in Ukraine, in response to recent nuclear threats [1][3][5] Collaboration Agreement - The collaboration will last for an initial three years, with the possibility of a three-year extension, focusing on stockpiling and distribution of PLX-R18 [1][2] - Pluri will produce PLX-R18, while Hemafund will utilize its biostorage and logistics expertise to ensure compliance with local regulations [2][9] Strategic Goals - The collaboration aims to secure external funding to establish an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals [4][5] - Hemafund will manage the storage and logistics of PLX-R18, ensuring rapid deployment in emergencies [4][9] Financial Implications - If successful, the collaboration could generate over $100 million in value for both parties based on the estimated cost per dose and projected stockpile [5][8] Context and Urgency - The collaboration is a proactive response to recent escalations in nuclear threats, highlighting the urgent need for effective radiation countermeasures in Ukraine [3][10] Company Background - Hemafund specializes in the preservation of umbilical cord blood and operates advanced cryostorage facilities in Ukraine [11] - Pluri is focused on developing cell-based products and solutions across various sectors, including regenerative medicine and food technology [12]

Core Viewpoint - Pluri Inc. has entered into an exclusive collaboration with Hemafund Ltd. to develop and distribute PLX-R18 cell therapy as a countermeasure against Hematopoietic Acute Radiation Syndrome (H-ARS) in Ukraine, in response to recent escalations in regional nuclear threats [1][3]. Group 1: Collaboration Agreement - The collaboration agreement is effective for an initial period of three years, with the possibility of a three-year extension [1]. - Pluri will produce and supply PLX-R18, while Hemafund will utilize its biostorage and logistics expertise to ensure compliance with local regulations [2][9]. - The collaboration aims to secure external funding to build an initial capacity of 12,000 doses of PLX-R18, sufficient to treat 6,000 individuals [4][5]. Group 2: Strategic Goals - The collaboration addresses Ukraine's urgent need for radiation countermeasures and ensures secure storage and rapid deployment of treatments [8]. - It seeks to attract public and private funding to support the development and accessibility of PLX-R18 [9]. - The collaboration may potentially generate over $100 million in value for both parties based on the estimated cost per dose and projected stockpile [5]. Group 3: Context and Need - The collaboration is a response to recent incidents, including a Russian drone strike on the Chernobyl nuclear power plant, highlighting the need for effective radiation countermeasures [3]. - H-ARS is caused by exposure to high levels of ionizing radiation, leading to severe health risks [6].

KEMPTTHAL, Switzerland and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Foodtech innovator Ever After Foods (EAF) and global food leader Bühler today announced an expansive cultivated meat collaboration to help food producers around the globe produce cultivated meat efficiently at mass scale. Bühler and Ever After Foods will work together to bring a commercial-scale cultivated meat production system, which allows commercial production at ten-fold lower scale than existing technologies, to market. Bühler ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition period from __________ to __________ Commission file number 001-31392 PLURI INC. (Exact name of registrant as specified in its charter) | Nevada | 98-0351734 | | --- | --- | | (State or other jurisdict ...

New investment follows recent private placement of $6.5 million with global investor and entrepreneur, Mr. Alejandro WeinsteinFunds are intended to support Pluri’s growth and execution strategy as a global leader in cell-based technology HAIFA, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq: PLUR) (TASE:PLUR) (“Pluri” or the “Company”), a leading biotechnology company leveraging its proprietary platform for cell-based solutions to create a collaborative network of ventures, today announced the ...